Meeting
2022 ASCO Annual Meeting
Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) compared to computed tomography (CT) for advanced renal cell carcinoma (RCC).
Authors
Shivanshan Pathmanathan
Department of Oncology, Royal Brisbane and Women’s Hospital, Brisbane, QLD, Australia
Shivanshan Pathmanathan , Arsalan Tariq , Chun Loo Gan , Adam Pearce , Handoo Rhee , Samuel Kyle , Sheliyan Raveenthiran , David Wong , Rhiannon McBean , Philip Marsh , Steven Goodman , Nattakorn Dhiantravan , Rachel Esler , Nigel Dunglison , Anojan Navaratnam , John Yaxley , Paul Thomas , David A. Pattison , Jeffrey C. Goh , Matthew Roberts
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4540)
DOI
10.1200/JCO.2022.40.16_suppl.4540
Abstract #
4540
Poster Bd #
31
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Prostate-specific membrane antigen ligand positron emission tomography (PSMA-PET) disease extent and overall survival (OS) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC): An international multicenter retrospective study.
First Author: Boris A. Hadaschik
Poster
2022 ASCO Annual Meeting
Prostate-specific membrane antigen PET response associates with radiographic progression-free survival following stereotactic ablative radiation therapy in oligometastatic castration-sensitive prostate cancer.
First Author: Philip Sutera
Poster
2021 ASCO Annual Meeting
Single-lesion PSMA protein expression and response to Lu-177 PSMA therapy in patients with castration-resistant prostate cancer.
First Author: Judith Stangl-Kremser
Poster
2016 Genitourinary Cancers Symposium
A phase I/IIa trial of prostate specific membrane antigen (PSMA) positron emission tomography (PET) imaging with 89Zr-Df-IAB2M in metastatic prostate cancer (PCa).
First Author: Michael J. Morris